{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T23:02:12Z","timestamp":1748041332123,"version":"3.37.3"},"reference-count":22,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T00:00:00Z","timestamp":1335139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Helsinki University Central Hospital EVO fund"},{"DOI":"10.13039\/100010114","name":"Yrj\u00f6 Jahnsson Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010114","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003756","name":"Biomedicum Helsinki Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Hemiplegia at stroke onset may be considered a contraindication for thrombolytic therapy. We describe the outcome of patients with ischaemic stroke presenting with hemiplegia and treated with intravenous alteplase (t<jats:styled-content style=\"fixed-case\">PA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients treated with t<jats:styled-content style=\"fixed-case\">PA<\/jats:styled-content> for acute ischaemic stroke between 1995 and 2010 were prospectively recorded in the <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>elsinki <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>troke <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>hrombolysis <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>egistry. Patients with basilar artery occlusion (<jats:styled-content style=\"fixed-case\">BAO<\/jats:styled-content>) were excluded. Hemiplegia was defined as no visible voluntary movement on ipsilateral arm and leg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of all treated patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a01579), we excluded those with <jats:styled-content style=\"fixed-case\">BAO<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a0152). Of remaining 1427 patients, 81 (6%) had hemiplegia at baseline. By 24\u00a0h, three had died and 20 retained their total hemiplegia. At day 7, a further nine had died, and 10 had persistent hemiplegia. A good 3\u2010month outcome, modified <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>ankin <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>cale (m<jats:styled-content style=\"fixed-case\">RS<\/jats:styled-content>, 0\u20132), was observed in 23%, independence in ambulatory function (m<jats:styled-content style=\"fixed-case\">RS<\/jats:styled-content> 3) in further 16%, while 9% were bedridden and 20% dead. A wide clinical spectrum of neurological deficits coexisted with hemiplegia. With advanced age, more neurological functions lost, and with early radiological signs, the prognosis of patients with hemiplegia deteriorated. With combined fixed eye deviation (<jats:italic>n<\/jats:italic>\u00a0=\u00a023), half were either bedridden (<jats:italic>n<\/jats:italic>\u00a0=\u00a03) or dead (<jats:italic>n<\/jats:italic>\u00a0=\u00a09) by 3\u00a0months, and fatal intracerebral haemorrhage were common (<jats:italic>n<\/jats:italic>\u00a0=\u00a05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hemiplegia at presentation should not prevent thrombolytic therapy by itself, as limb movements are likely to return, and two of five thrombolysis\u2010treated patients will walk independently by 3\u00a0months. With combined fixed eye deviation, the outcome is poorer and haemorrhagic complications are common.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1331.2012.03729.x","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T07:11:01Z","timestamp":1335165061000},"page":"1235-1238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hemiplegia and thrombolysis"],"prefix":"10.1111","volume":"19","author":[{"given":"A.","family":"Meretoja","sequence":"first","affiliation":[{"name":"Department of Neurology Helsinki University Central Hospital  Helsinki Finland;"},{"name":"Florey Neuroscience Institutes Melbourne Brain Centre at the Royal Melbourne Hospital Department of Medicine, University of Melbourne  Melbourne Australia;"},{"name":"Department of Neurology The Royal Melbourne Hospital  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Strbian","sequence":"additional","affiliation":[{"name":"Department of Neurology Helsinki University Central Hospital  Helsinki Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Putaala","sequence":"additional","affiliation":[{"name":"Department of Neurology Helsinki University Central Hospital  Helsinki Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kaste","sequence":"additional","affiliation":[{"name":"Department of Neurology Helsinki University Central Hospital  Helsinki Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Tatlisumak","sequence":"additional","affiliation":[{"name":"Department of Neurology Helsinki University Central Hospital  Helsinki Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60491-6"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.4.811"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.21.2019"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530130023023"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08020-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804656"},{"key":"e_1_2_7_9_1","unstructured":"Food and Drug Administration.Alteplase product approval information\u2013licensing action5\/15\/02.2002."},{"key":"e_1_2_7_10_1","unstructured":"European Medicines Agency.Summary information on a referral opinion following an arbitration pursuant to article 29 of directive 2001\/83\/EC for Actilyse. International non\u2010proprietary name (INN): Alteplase.2002."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.181486"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000131083"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.576140"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.15.1862"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.11.2220"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70247-7"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.604090"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/NPT.0b013e318198a010"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9993(00)90102-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318245d2a9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23546"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15692-4"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.589317"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2012.03729.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2012.03729.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:30:03Z","timestamp":1698658203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2012.03729.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,23]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1468-1331.2012.03729.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03729.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"type":"print","value":"1351-5101"},{"type":"electronic","value":"1468-1331"}],"subject":[],"published":{"date-parts":[[2012,4,23]]},"assertion":[{"value":"2011-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}